

**ERA-NET on Translational Cancer Research (TRANSCAN)  
Joint Transnational Call for Proposals 2012 (JTC 2012) on:**

**“Translational research on primary and secondary  
prevention of cancer”**

---

## **Guidelines for Applicants**

---

### **Submission deadlines**

**Pre-proposals: 15 February 2013 at 17:00 CET**

**Full proposals: 24 June 2013 at 17:00 CEST**

### **Useful links**

[Link to call text](#)

[Link to pre-proposal application form](#)

[Link to electronic proposal submission](#) (available from 14 January 2013)

For further information, please visit [www.transcanfp7.eu](http://www.transcanfp7.eu)

or contact the **Joint Call Secretariat (JCS)** at:

**French National Cancer Institute (INCa), France**

**Cancer Biology Department**

**E-mail: [egerbaud@institutcancer.fr](mailto:egerbaud@institutcancer.fr)**

**Tel. +33 (0)1 41 10 14 16**



## Table of contents

---

<b>BACKGROUND .....</b>	<b>3</b>
<b>PROPOSAL SUBMISSION.....</b>	<b>3</b>
<b>ELIGIBILITY CHECK .....</b>	<b>4</b>
<b>PRE-PROPOSAL STRUCTURE .....</b>	<b>5</b>
<b>FULL PROPOSAL STRUCTURE .....</b>	<b>6</b>
<b>PROJECT START AND CONSORTIUM AGREEMENT.....</b>	<b>10</b>
<b>ANNEX 1. CONTACT INFORMATION OF THE NATIONAL/REGIONAL FUNDING ORGANISATIONS.....</b>	<b>11</b>
<b>ANNEX 2. NATIONAL/REGIONAL FUNDING ORGANISATIONS' REGULATIONS .....</b>	<b>15</b>
<b>Austria .....</b>	<b>15</b>
<b>Belgium: Flanders .....</b>	<b>16</b>
<b>France.....</b>	<b>18</b>
<b>Germany .....</b>	<b>20</b>
<b>Israel .....</b>	<b>21</b>
<b>Italy .....</b>	<b>22</b>
<b>Latvia .....</b>	<b>24</b>
<b>Luxembourg.....</b>	<b>26</b>
<b>The Netherlands.....</b>	<b>27</b>
<b>Norway.....</b>	<b>28</b>
<b>Norway.....</b>	<b>29</b>
<b>Poland.....</b>	<b>30</b>
<b>Portugal .....</b>	<b>32</b>
<b>Romania .....</b>	<b>33</b>
<b>Slovak Republic .....</b>	<b>34</b>
<b>Turkey.....</b>	<b>36</b>

## BACKGROUND

Under the umbrella of TRANSCAN ERA-Net on Translational Cancer Research, 17 funding organisations have agreed to launch the Second Joint Transnational Call (JTC) in 2012 for collaborative research projects on **“Translational research on primary and secondary prevention of cancer”**.

The participating TRANSCAN funding organisations emphasise the promotion of innovative interdisciplinary collaboration and truly translational research projects.

The research projects submitted within this call will be based on novel ideas stemming from consolidated previous results and will be endowed with a strong translational research orientation, i.e. i) bench to bed studies allowing a rapid implementation into public health-related decisions or into the clinics, or ii) bed to bench studies, based on previous sound clinical results and aiming at their mechanistic understanding.

Project proposals must clearly demonstrate the potential health impact as well as the added-value of transnational collaboration. The sharing of relevant results, data sets and/or resources within international research consortia will be a prerequisite for funding. The research proposals should be built on an effective, multidisciplinary and multi-professional collaboration between academic, clinical, epidemiological or public health research teams and industry. Researchers' exchanges within the consortium are strongly encouraged.

## PROPOSAL SUBMISSION

There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals. In both cases, a single joint proposal document in English should be prepared by the partners and submitted electronically by the coordinator as a PDF file to the Joint Call Secretariat (JTC), using the application forms provided on the TRANSCAN website (<http://www.transcanfp7.eu>). All fields requested by the electronic system are mandatory. Original signed versions of either pre- or full proposal will not be required. In the case of full proposals only, a scanned version of the first page signed by the coordinator will be required when submitting. Joint full proposals will be accepted only from applicants explicitly invited by the JCS to submit them.

Both pre-proposals and full proposals must be submitted to <https://www.pt-it.de/ptoutline/application/cancer12> within the deadlines indicated below.

**Pre-proposals must be submitted to and received by the JCS no later than 15 February 2013 at 17.00 (Central European Time).**

**Full proposals must be received by the JCS no later than 24 June 2013 at 17.00 (Central European Summer Time).**

Call deadlines are final and will be strictly enforced. The electronic system will not allow submissions after call deadlines. Applicants are recommended to submit their proposals beforehand as the electronic system might be overloaded at the time of the application deadlines.

## **ELIGIBILITY CHECK**

Prior to submitting the proposal, applicants should refer to the national eligibility criteria and requirements (Annex 2) and should contact their respective national/regional funding organisation contact points for additional clarification (see Annex 1: Contact information of the national/regional funding organisations).

**NOTE:** *An eligibility check before the pre-proposal submission is mandatory for the following funding organisations: The Ministry of Health (MOH), Italy and The Dutch Cancer Society (DCS), The Netherlands.*

The JCS will assess proposals to ensure that they meet the call's formal criteria [e.g. date of submission; number of participating research groups, type of project partners (academic, clinical/public health and industrial/SMEs), and inclusion of all necessary information in English]. In parallel, the JCS will forward the proposals to the relevant TRANSCAN national/regional funding organisations that will perform a formal check of compliance with their respective eligibility criteria. Proposals passing both checks will be forwarded to independent international scientific experts for evaluation.

Please note that after submission of the proposal it is not possible to amend it or to add further documents.

For additional information, please contact:

**JTC 2012 Joint Call Secretariat (JCS)**

**Contact person: Estelle GERBAUD**

**E-mail: [egerbaud@institutcancer.fr](mailto:egerbaud@institutcancer.fr)**

Tel.: +33 (0)1 41 10 14 16

## PRE-PROPOSAL STRUCTURE

Applications must be submitted using the pre-proposal form provided on the TRANSCAN website (<http://www.transcanfp7.eu>), and respect the format (Arial font, size 11, DIN-A4, single-spaced, margins of 2.5) and length indicated for each section otherwise they will be rejected without further review. The proposal must be written in English and submitted to the JCS by the project coordinator in a single PDF file through the electronic system.

Pre-proposals must include the following information:

1. Project title and acronym.
2. Project duration.
3. Name and full affiliation of the project coordinator designated by the consortium to act as its representative.
4. Names and full affiliations of the principal investigators (one per research group partner in the joint transnational project).
5. Total requested funding (€).
6. Keywords (3 to 7) representing: the scientific content [(primary or secondary cancer prevention; type of cancer; specific area(s) (see Call text, chapter 2. Aim of the call)]; the methodological and technological approach(es).
7. Adherence of the proposal to the scope, aims and specific content of the call (see Call text, chapter 2. Aim of the call):

### Primary cancer prevention

- A. Identification and validation of cancer etiology drivers, based on molecular epidemiology-derived evidences.
- B. Identification and validation of cancer preventive or predisposing factors, based on molecular epidemiology-derived evidences.
- C. Investigation, prompted by clinical trials results, of molecular mechanisms of action of potentially cancer preventive drugs and of their combination, with a particular focus on the identification of modalities for inducing synergistic effects.
- D. Clinical prevention trials of cancer-preventive agents.
- E. Development of strategies and tools for immune prevention of cancer.

### Secondary cancer prevention

- A. Validation of biomarkers and development of technologies and methodologies for early detection and cancer screening.
- B. Research on integration of age and co-morbidity, in terms of underlying mechanisms.

8. Summary of the project (once converted into PDF document: max. 5 pages). The summary should contain:

- a. Description of the project rationale, in terms of medical need, and of the present state of the art in the field(s).
- b. Description of the research hypothesis(es), of the project objectives, and of the work program, including methodology, with particular regard to the study design, the study population(s), and the statistical and biostatistical analysis and power calculations. This section should highlight the innovative approach, originality and feasibility of the project.
- c. Information about the experience of the research consortium partners in the field; the management structure and related implementation plan; added value of the proposed transnational collaboration.
- d. Information about potential impact on cancer prevention and control with reference to the development, dissemination and use of project results.
- e. References (one page maximum) and diagrams, figures, etc. (one page maximum) should be added in an appendix.

**Please note: if the proposal comprises a clinical trial, the section 11 “Clinical trial description” of the pre-proposal application form, should be completed, in addition to the summary of the project.**

9. Capacity building and training activities (optional section) (max. ½ page). Please specify whether the project will include capacity building and training activities. If so, please describe briefly the nature and purpose of the planned activities taking into account the information described in the call text. The separated budget will have to be mentioned in the financial plan (section 12) in the appropriate line.

10. Brief CV for each research partner (i.e. the project coordinator and each principal investigator) including a description of the main domain of research and a list of the five most relevant publications within the last five years regarding the proposal (once converted into PDF document: max. 1 page for each partner).

11. Clinical trial description (if applicable).

12. Financial plan of the project.

**IF APPLICABLE:** A signed written confirmation that the project partner from a country/region not participating in the JTC 2012 has secured its funding at the stage of pre-proposal submission.

## **FULL PROPOSAL STRUCTURE**

**The information given in the pre-proposal is binding. Thus, any fundamental changes between the pre- and full proposals (e.g. composition of the consortia, objectives of the**

**project, etc.) must be immediately communicated to the JCS with detailed justification and changes will only be allowed by the Call Steering Committee (CSC) under exceptional circumstances.**

Please note that it is mandatory that the applicants use the **full proposal application form** provided on the TRANSCAN website ([www.transcanfp7.eu](http://www.transcanfp7.eu)), and that the full proposal document respects the format and the length indicated. **Full proposals not complying with these rules will be rejected.**

Full proposals must include the following information:

- Project title and acronym.
- Project duration.
- Total requested funding.
- Keywords (3 to 7) representing: the scientific content [(primary or secondary cancer prevention); type of cancer; specific area(s) (see Call text, chapter 2. Aim of the call)]; the methodological and technological approach(es).
- Publishable project abstract (max. ½ page) (Please note that if your proposal is selected for funding, the abstract you submit on your application form will be published on the TRANSCAN website).
- Name and signature of the project coordinator.
- Names and full affiliations of each principal investigator partner in the research consortium.
- Project description:
  1. Background and rationale (medical need and present state of the art in the research field(s) (max. 2 pages).
  2. Description of the objectives (overall and at the work package level).
  3. Research hypothesis(es) and work plan (max. 20 pages).

This section should contain:

- a. Description of the research hypothesis(es) and of the work plan, including a general overview of the entire consortium, and the rationale of the work packages. This section should highlight the following aspects: innovative approach, originality, feasibility of the project and expected progress beyond the state-of-the-art; availability and quality of preliminary data; international competitiveness; relevance and clarity of the objectives with respect to the specific medical need and aims of the call.
- b. Description of the methodology and feasibility of the proposal and of the work packages. The relevance, originality and soundness of the methodology and statistical analysis should be highlighted, with particular regard to the specific aspects detailed in the “Guidelines for applicants”.

- c. Description of the relevant infrastructures and resources to be used for the implementation of the work plan, concept of data and material acquisition and storage, availability of biological resources, data management and elaboration (including assessment of statistical power aspects). Please refer to the “Guidelines for applicants” for the details.
  - d. Description of the research consortium governance and management and of project coordination. Please: i) provide a description of the governance and management structure and of project coordination planning (meeting, monitoring, etc); ii) define the responsibilities and project effort (expressed in person months) of each participating research group per work package; iii) provide a graphic representation of the project time plan (Gantt chart).
  - e. References.
  - f. Diagrams and figures.
4. Diagram which compiles the work plan, the contribution of the partners to each work package and their interactions (Pert diagram) (max. 1 page).
  5. Description of the added value of the collaboration in the proposed transnational project (max. 1 page). This section should describe the quality of the transnational research consortium, illustrating: i) the level of expertise of the individual partner research teams in the field(s) of the proposal (team scientific track record, publications, patents, etc.; ii) the quality of the collaboration between the research teams and added value of the research consortium with respect to the individual teams.
  6. Description of past and ongoing research projects of each participating group related to the present topic, indicating funding sources (include at least: ID number, amount and duration of funded project; funding agency) and possible overlaps with the proposal (max. ½ page per research group).
  7. Potential medical impact and exploitation/dissemination of project results (max. ½ page). Describe the potential impact of the expected results on cancer prevention and control, in terms of translation into public health or clinical practices and/or into pharmaceutical/industrial applications; appropriateness of measures for the dissemination and/or exploitation of project results including socio-economic aspects and anticipation of intellectual property issues (patenting, industrial exploitation, marketing, etc.).
  8. Description of existing or potential patents (own or third party) and present/future position with regard to intellectual property rights, both within and outside the consortium (i.e. freedom to operate, barriers to sharing materials or results), if applicable (max. ½ page).
  9. Justification of requested budget. Please provide specific information about the use of the requested funds and specify co-funding from other sources supporting the project, if applicable) (max. ½ page per research group).

10. Ethical and legal issues of the project proposal, Please provide confirmation that the study complies with local, national and EU regulations, concerning informed consent and other legal requirements for human experimentations, data protection, and use of animals, if applicable (max. ½ page).
11. Brief CV for each research partner (i.e. the project coordinator and each principal investigator) including a description of the main domain of research and a list of the five most relevant publications within the last five years, demonstrating the competence to carry out the project (max. 1 page for each partner).
12. Capacity building and training activities (optional section) (max. 1 page) (Please refer to the call text for the specific modalities of this section). This section must include: a) description of capacity building and training activities and relevance to the proposal objectives; b) description of the candidate [CV, background (scientific, medical, etc.); scientific production; current work; coherence of the training with the CV,]; c) description of the host team (expertise in the field and qualification in research of the responsible person); d) justification of the additional separate budget needed for these specific activities.
13. Clinical trial description (if applicable). Please note: if a proposal comprises the implementation of a clinical trial, this section should be completed in addition to the sections 1-12. If a proposal is focused exclusively on the implementation of a clinical trial, only the section 13 of this form should be completed, unless additional information needs to be provided under the sections 1-12. In any instance, if an issue is addressed in a specific section, please refer to the pertinent section.
14. Financial plan for each research consortium partner.
15. Number of person months of personnel participating in the project for which no funding is requested (if applicable).
16. Signed declaration by the project coordinator and by the principal investigators partners in the project concerning the agreement of their respective team members to participate in the proposal (signed PDF).
17. Reviewers to be excluded from refereeing this proposal (optional: please note that up to three potential reviewers can be indicated and that the CSC will respect these requests provided that they do not interfere with the objective and thorough evaluation of the proposal).

Additional information must be provided if requested by national/regional funding organisations, based on their respective eligibility criteria.

## **PROJECT START AND CONSORTIUM AGREEMENT**

A Consortium agreement (CA) should be signed between the partners of funded projects for a proper conduct of the project activities, finances, intellectual right properties (IPR) and to avoid disputes which might be detrimental to the completion of the project.

The research consortium is strongly encouraged to sign the CA before the official project start date. Upon request, the CA must be made available to the concerned TRANSCAN JTC 2012 funding organisations.

Consortium partners of projects selected for funding must fix a common project start date, which would be the reference date for yearly and final reports and extensions. The project start date should fall in April 2014. This common project start date must appear in the CA.

## ANNEX 1. CONTACT INFORMATION OF THE NATIONAL/REGIONAL FUNDING ORGANISATIONS

Country/Region	Participating Funding Organisations	Website	National Contact Points
Austria	Austrian Science Fund (FWF)	<a href="http://www.fwf.ac.at/">http://www.fwf.ac.at/</a>	<b>Dr. Stephanie RESCH</b> Austrian Science Fund Haus der Forschung, Sensengasse 1 1090 Vienna, Austria Tel: +43-1-505 67 40-8201 E-mail: <a href="mailto:stephanie.resch@fwf.ac.at">stephanie.resch@fwf.ac.at</a>
Belgium	Research Foundation - Flanders (FWO)	<a href="http://www.fwo.be/">http://www.fwo.be/</a>	<b>Dr. Olivier BOEHME</b> Senior Science Administrator Research Foundation - Flanders Egmonstraat 5 B-1000 Brussels, Belgium Tel. +32 2 550 15 45 E-mail: <a href="mailto:olivier.boehme@fwo.be">olivier.boehme@fwo.be</a>
France	French National Cancer Institute (INCa)	<a href="http://www.e-cancer.fr/">http://www.e-cancer.fr/</a>	<b>Estelle GERBAUD, PharmD</b> Cancer Biology Department / Research and Innovation Division 52 avenue André Morizet 92513 Boulogne Billancourt Cedex, France Tel: +33 (0)1 41 10 14 16 E-mail: <a href="mailto:egerbaud@institutcancer.fr">egerbaud@institutcancer.fr</a>
	ARC French Foundation for Cancer Research (ARC Foundation)	<a href="http://www.arc-cancer.net">http://www.arc-cancer.net</a>	<b>Ms. Christelle DAVID-BASEI, PhD</b> Scientific Director Fondation ARC pour la recherche sur le cancer Direction de l'Action Scientifique 9 Rue Guy Moquet – BP 90003 94803 Villejuif Cedex, France Tel : +33 (0)1 45 59 59 44 E-mail: <a href="mailto:cdavid-basei@arc-cancer.net">cdavid-basei@arc-cancer.net</a>  <b>Ms. Nancy ABOU-ZEID, PhD</b> Scientific Officer – Partnerships Fondation ARC pour la recherche sur le cancer Direction de l'Action Scientifique 9 Rue Guy Moquet – BP 90003 94803 Villejuif Cedex, France Tel : +33 (0)1 45 59 58 44 E-mail: <a href="mailto:nabou-zeid@arc-cancer.net">nabou-zeid@arc-cancer.net</a>
Germany	Federal Ministry of Education and Research (BMBF) / PT-DLR	<a href="http://www.gesundheitsforschung-bmbf.de">http://www.gesundheitsforschung-bmbf.de</a> <a href="http://www.gesundheitsforschung-bmbf.de/de/4639.php">http://www.gesundheitsforschung-bmbf.de/de/4639.php</a>	<b>Project Management Agency of the German Aerospace Centre</b> (PT-DLR) - Health Research-Heinrich-Konen-Str. 1 53227 Bonn, Germany Tel: +49 (0)228/3821-1210 Fax: +49 (0)228/3821-1257 E-mail: <a href="mailto:gesundheitsforschung@dlr.de">gesundheitsforschung@dlr.de</a>
Israel	The Chief Scientist Office of the Ministry of Health (CSO-MOH)	<a href="http://www.health.gov.il">http://www.health.gov.il</a>	<b>Dr. Benny LESHEM</b> The Medical Research Administration Chief Scientist Office Israeli Ministry of Health 2, Ben Tabai St. Jerusalem 91010, Israel Tel: +972-2-568-1208 E-mail: <a href="mailto:benny.leshem@moh.health.gov.il">benny.leshem@moh.health.gov.il</a>

<p>Italy</p>	<p>Ministry of Health (MoH)</p>	<p><a href="http://www.salute.gov.it">http://www.salute.gov.it</a></p>	<p><b>Dr. Maria FERRANTINI</b>          Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions          Ministry of Health          Viale Giorgio Ribotta, 5          00144 Rome, Italy          Tel: +39 065994.2684          E-mail: <a href="mailto:transcan@sanita.it">transcan@sanita.it</a></p> <p><b>Dr. Tiziana CATENA</b>          Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions          Ministry of Health          Viale Giorgio Ribotta, 5          00144 Rome, Italy          Tel: +39 065994.3528          E-mail: <a href="mailto:transcan@sanita.it">transcan@sanita.it</a></p> <p><b>Dr. Silvia PARADISI</b>          Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions          Ministry of Health          Viale Giorgio Ribotta, 5          00144 Rome, Italy          Tel: +39 065994.2684          E-mail: <a href="mailto:transcan@sanita.it">transcan@sanita.it</a></p>
<p>Latvia</p>	<p>Latvian Academy of Sciences (LAS)</p>	<p><a href="http://www.lza.lv">http://www.lza.lv</a></p>	<p><b>Dr. Maija BUNDULE</b>          Centre of European Programs          Latvian Academy of Sciences          1 Akademijas laukums, Riga, 1050          Latvia          Tel: +371 67227790          E-mail: <a href="mailto:maija.bundule@lza.lv">maija.bundule@lza.lv</a></p> <p><b>Dr. Uldis BERKIS</b>          Centre of European Programs          Latvian Academy of Sciences          1 Akademijas laukums, Riga, 1050          Latvia          Tel: +371 67409242          E-mail: <a href="mailto:uberkis@latnet.lv">uberkis@latnet.lv</a></p>
<p>Luxembourg</p>	<p>National Research Fund (FNR)</p>	<p><a href="http://www.fnr.lu">http://www.fnr.lu</a></p>	<p><b>Frank GLOD</b>          Tel: +352 26192533          E-mail: <a href="mailto:frank.glod@fnr.lu">frank.glod@fnr.lu</a></p>
<p>The Netherlands</p>	<p>Dutch Cancer Society (DCS)</p>	<p><a href="http://www.kwfkankerbestrijding.nl">http://www.kwfkankerbestrijding.nl</a></p>	<p><b>Ms. Wia TIMMERMAN</b>          KWF Kankerbestrijding          Delflandlaan 17/ Postbus 75508          1070 AM Amsterdam          The Netherlands          Tel: + 31 20 5700520          Email: <a href="mailto:wtimmerman@kwfkankerbestrijding.nl">wtimmerman@kwfkankerbestrijding.nl</a></p> <p><b>Ms. Merel HOOZEMANS</b>          KWF Kankerbestrijding          Delflandlaan 17/ Postbus 75508          1070 AM Amsterdam          The Netherlands          Tel: + 31 20 5700520</p>

			E-mail: <a href="mailto:mhoozemans@kwfkankerbestrijding.nl">mhoozemans@kwfkankerbestrijding.nl</a>
Norway	Norwegian Cancer Society (NCS)	<a href="http://www.kreftforeningen.no">www.kreftforeningen.no</a>	<b>Dr. Nina ANENSEN</b> Kreftforeningen Postboks 4, Sentrum 0101 Oslo Norway Tel: +47 93 00 74 07 E-mail: <a href="mailto:nina.anensen@kreftforeningen.no">nina.anensen@kreftforeningen.no</a>
Norway	The Research Council of Norway (RCN)	<a href="http://www.rcn.no">http://www.rcn.no</a>	<b>Henrietta BLANKSON</b> The Research Council of Norway, Division for Society and Health, Department for Health Boks 2700 St. Hanshaugen N-0131 Oslo E-mail: <a href="mailto:hbl@rcn.no">hbl@rcn.no</a> Tel: + 47 22 03 71 76  <b>Karianne SOLAAS</b> The Research Council of Norway, Division for Society and Health, Department for Health Boks 2700 St. Hanshaugen N-0131 Oslo E-mail: <a href="mailto:kso@rcn.no">kso@rcn.no</a> Tel: +47 22 03 70 84
Poland	National Centre for Research and Development (NCBiR)	<a href="http://www.ncbr.gov.pl">http://www.ncbr.gov.pl</a>	<b>Mr. Marcin CHMIELEWSKI</b> National Centre for Research and Development (NCBR) Section for Research Projects BIOMED Nowogrodzka Str. 47a, 00-695 Warsaw, Poland Tel: +48 22 39 07 109 E-mail: <a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a>  <b>Ms. Malgorzata ZIEMINSKA</b> National Centre for Research and Development (NCBR) Section for Research Projects BIOMED Nowogrodzka Str. 47a, 00-695 Warsaw, Poland +48 22 39 07 140 E-mail: <a href="mailto:malgorzata.zieminska@ncbr.gov.pl">malgorzata.zieminska@ncbr.gov.pl</a>
Portugal	Foundation for Science and Technology (FCT)	<a href="http://www.fct.pt">www.fct.pt</a>	<b>Cristiana LEANDRO</b> Departamento de Relações Internacionais (DRI) Fundação para a Ciência e Tecnologia Av. D. Carlos I, 126 1249-074 Lisboa Portugal Tel.: +351 213 924 381 E-mail: <a href="mailto:cristiana.leandro@fct.pt">cristiana.leandro@fct.pt</a>
Romania	Institute of Oncology Prof. Dr. Alexandru Trestioreanu (IOB)	<a href="http://www.iob.ro">http://www.iob.ro</a>	<b>Prof. Dr. Rodica ANGHEL, PhD MD</b> Institute of Oncology "Prof Dr AI Trestioreanu" Bucharest 252 Fundeni street, Sector 2, Bucharest, Romania Tel: +40 212271400

			<p>Email: <a href="mailto:rodicamanghel@gmail.com">rodicamanghel@gmail.com</a></p> <p><b>Mr. Sabin CINCA, PhD</b>          Institute of Oncology "Prof Dr Al Trestioreanu" Bucharest          252 Fundeni street, Sector 2,          Bucharest, Romania          Tel. +40.213183561          E-mail: <a href="mailto:sabincinca@yahoo.com">sabincinca@yahoo.com</a></p>
Slovakia	Slovak Academy of Sciences (SAS)	<a href="http://www.sav.sk">http://www.sav.sk</a>	<p><b>Mr. Jan BARANCIK, PhD</b>          Department for International Cooperation of SAS,          Slovak Academy of Sciences,          Štefánikova 49          814 38 - Bratislava, Slovak Republic          Tel: +421 2 5751 0137          E-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a></p> <p><b>Ms. Anna GÁBELOVÁ, PhD</b>          Cancer Research Institute          Slovak Academy of Sciences Vlarska          7833 91 - Bratislava, Slovak Republic          Tel: +421 2 59327-512, 202, 502, 526          E-mail: <a href="mailto:exongaba@savba.sk">exongaba@savba.sk</a></p> <p><b>Ms. Iveta HERMANOVSKÁ</b>          Department for International Cooperation of SAS,          Slovak Academy of Sciences,          Štefánikova 49          814 38 - Bratislava, Slovak Republic          Tel: +421 2 5751 0136          E-mail: <a href="mailto:hermanovska@up.upsav.sk">hermanovska@up.upsav.sk</a></p>
Turkey	The Scientific and Technological Research Council of Turkey (TÜBİTAK)	<a href="http://www.tubitak.gov.tr/">http://www.tubitak.gov.tr/</a>	<p><b>Ms. Nihan ERYILMAZ</b>          TÜBİTAK Tunus Caddesi No:80          06100 Kavaklıdere / Ankara, Turkey          Tel: + 90 312 468 53 00 / 1007          E-mail: <a href="mailto:nihan.eryilmaz@tubitak.gov.tr">nihan.eryilmaz@tubitak.gov.tr</a></p>

## ANNEX 2. NATIONAL/REGIONAL FUNDING ORGANISATIONS' REGULATIONS

<b>Country</b>	<b>AUSTRIA</b>
<b>Funding organisation</b>	<a href="#">Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung - FWF)</a>
<b>National contact persons</b>	<b>Dr. Stephanie Resch</b> Phone: +43 (1) 505 67 40-8201, E-mail: <a href="mailto:stephanie.resch@fwf.ac.at">stephanie.resch@fwf.ac.at</a>
<b>National programme</b>	
<b>Funding commitment</b>	1 Mio €
<b>Anticipated number of fundable project partners</b>	4 projects
<b>Maximum funding per grant awarded to a project partner</b>	No limit / amount of typical (sub)project: ~0.3 Mio. € for a three-year project
<b>Eligibility of projects</b>	Joint research projects
<b>Eligibility of a partner as a beneficiary institution</b>	
<b>Eligibility of principal investigator or other research team member</b>	Individual researcher or teams of researchers, working in any kind of non-profit organization: e.g. University, University hospital, Non-university research institute <i>Please refer also to the general FWF Funding Guidelines: <a href="http://www.fwf.ac.at/de/downloads/pdf/fwf_funding_guidelines.pdf">http://www.fwf.ac.at/de/downloads/pdf/fwf_funding_guidelines.pdf</a></i>
<b>Eligibility of costs, types and their caps</b>	Only project-specific costs (see rules for FWF stand-alone project) No overhead allowed (according to national regulation there are 5% general costs)
<b>National phase</b>	Only Proposals reaching 2nd stage (full proposal) of the call: PI has to submit one-page project Summary in English and in German, application forms (application form, itemization of requested funding and forms for international research partners) and Justification for the costs details please see <a href="http://www.fwf.ac.at/de/applications/i-internationale_kooperationsprojekte.html">http://www.fwf.ac.at/de/applications/i-internationale_kooperationsprojekte.html</a>
<b>Further guidance</b>	<a href="http://www.fwf.ac.at/de/applications/i-internationale_kooperationsprojekte.html">http://www.fwf.ac.at/de/applications/i-internationale_kooperationsprojekte.html</a>

<b>Country</b>	<b>BELGIUM: FLANDERS</b>
<b>Funding organisation</b>	Research Foundation – Flanders (FWO)
<b>National contact persons</b>	<b>Dr. Olivier Boehme</b>
<b>National programme</b>	New Research Projects
<b>Funding commitment</b>	€ 200.000
<b>Anticipated number of fundable project partners</b>	1
<b>Maximum funding per grant awarded to a project partner</b>	€ 200.000
<b>Eligibility of projects</b>	<p>Art. 9 of the FWO-regulation on the regular research projects is applicable. In this article is stated who can apply as a (co-)promoter for a research project (here only those cases that are relevant for cancer research are listed):</p> <p><u>Promoter:</u></p> <ul style="list-style-type: none"> <li>– a professor with an appointment of more than 10% at a Flemish university;</li> <li>– a professor with an appointment of 10% at a Flemish university and a main task as researcher;</li> <li>– a professor with an appointment of 5% at a Flemish university and with an appointment as (assistant) clinical head or an equal function in a university hospital;</li> <li>– a research director of FWO;</li> <li>– a Flemish beneficiary of an ERC Starting Grant, an ERC Advanced Grant or an allowance in the FWO-funding programme Odysseus II.</li> </ul> <p><u>Co-promoter:</u></p> <p>All co-promoters have to be researchers at at least postdoctoral level in at least one of the following types of organisations:</p> <ul style="list-style-type: none"> <li>– a Flemish university;</li> <li>– a Flemish research institution;</li> <li>– a Flemish university hospital;</li> <li>– the Transnational university Limburg;</li> <li>– a federal scientific institution, if the co-promoter belongs to the Dutch language register.</li> </ul> <p>Researchers from outside Flanders can be involved as co-promoter without being entitled to receive funding from the FWO and insofar this cooperation is relevant for the project.</p> <p>If more than one universities are involved in the project, at least one promoter or co-promoter of each university has to fulfill the above mentioned eligibility criteria as well as to occupy a position covering entirely the period of the project that is applied for.</p> <p>The criteria have to be met with at the start of the project at the latest, which has to be proven at the date of the submission.</p>

<b>Eligibility of a partner as a beneficiary institution</b>	See under 'Eligibility of projects'.
<b>Eligibility of principal investigator or other research team member</b>	See under 'Eligibility of projects'.
<b>Eligibility of costs, types and their caps</b>	<p>Funding money can be used for staff, consumables and infrastructure. The minimal and maximal amounts of money allowed per cost category, as applicable for the regular FWO-projects, are not applicable for the projects funded by FWO in ERA-NET. However, for staff costs the same lump sums are applicable as in the regular projects, i.e.: 60.000 € for a scientific staff member and 50.000 € for a technical staff member.</p> <p>Moreover, FWO pays the host institutions of a project 6% overhead on top of the funding amount.</p> <p>Funding cannot be used for training activities, apart from the opportunity for a researcher appointed within the project to obtain a PhD on the basis of the results from his/her project research.</p>
<b>National phase</b>	The FWO-funding scheme for New Research Projects is opened one time a year.
<b>Further guidance</b>	<p><a href="http://www.fwo.be/Nieuw-onderzoeksproject.aspx">http://www.fwo.be/Nieuw-onderzoeksproject.aspx</a></p> <p>For more information also the NCP can be contacted.</p>

<b>Country</b>	<b>FRANCE</b>	
<b>Funding organisations</b>	<a href="#">French National Cancer Institute (INCa)</a>	<a href="#">ARC French Foundation for Cancer Research (Foundation ARC)</a>
<b>National contact persons</b>	<p><b>For INCa:</b></p> <p><b>Estelle GERBAUD, PharmD</b>  <b>Cancer Biology Department / Research and Innovation Division</b>  52 avenue André Morizet  92513 Boulogne Billancourt Cedex  Email : <a href="mailto:egerbaud@institutcancer.fr">egerbaud@institutcancer.fr</a>  Phone: + 33 (0)1 41 10 14 16</p>	<p><b>For ARC Foundation:</b></p> <p><b>Ms. Christelle DAVID-BASEI, PhD</b>  <b>Scientific Director</b>  Fondation ARC pour la recherche sur le cancer  Direction de l'Action Scientifique 9 Rue Guy Moquet – BP 90003  94803 Villejuif Cedex, France  Tel : +33 (0)1 45 59 59 44  E-mail: <a href="mailto:c david-basei@arc-cancer.net">c david-basei@arc-cancer.net</a></p> <p><b>Ms. Nancy ABOU-ZEID, PhD</b>  <b>Scientific Officer – Partnerships</b>  Fondation ARC pour la recherche sur le cancer  Direction de l'Action Scientifique  9 Rue Guy Moquet – BP 90003  94803 Villejuif Cedex, France  Tel : +33 (0)1 45 59 58 44  E-mail: <a href="mailto:nabou-zeid@arc-cancer.net">nabou-zeid@arc-cancer.net</a></p>
<b>National programme</b>	French National Cancer Plan 2009-2013 – Action 1.1: Strengthen translational research through dedicated funding based on calls for proposals	
<b>Funding commitment</b>	INCa: 1.5M euro	ARC Foundation: 0.3 to 0.5M euro
<b>Anticipated number of fundable project partners</b>	INCa : From 5 to 10 research teams	ARC Foundation: From 1 to 3 research teams
<b>Maximum funding per grant awarded to a project partner</b>	INCa and ARC foundation do not have a maximum funding per grant; the amount depends on the scientific and medical needs and should be justified in the requested budget.	
<b>Eligibility of projects</b>	Please refer to the call text	
<b>Eligibility of a partner as a beneficiary institution</b>	<ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> </ul>	
<b>Eligibility of principal investigator or other research team member</b>	<p><i>Reminder: Each transnational consortium must nominate a coordinator from one of the JTC 2012 countries/region. The coordinator will be responsible for the internal scientific management and for the external representation towards the JCS and the CSC. Each consortium partner will be represented by one principal investigator, who will be the contact person for the respective national/regional funding organization.</i></p> <ul style="list-style-type: none"> <li>- Public research institutions (university, EPST, EPIC, etc.)</li> </ul>	

	<ul style="list-style-type: none"> <li>- Non-profit organisations (associations, foundations, etc.)</li> <li>- Hospitals or other health care providers (CHU, CRLCC, etc.)</li> <li>- Industrial companies could participate if the group is able to secure its own funding however the Project Coordinator could not come from an industrial partner.</li> </ul> <p><i>Please note that for the reason that a personal investment is necessary for the good progress of the project, the PI is not allowed to coordinate simultaneously more than 3 projects funded by INCa.</i></p>
<p><b>Eligibility of costs, types and their caps</b></p>	<p><b>For the research project:</b></p> <ul style="list-style-type: none"> <li>- Equipment (up to 150 000 € including taxes)</li> <li>- Consumables and subcontracting</li> <li>- Personnel costs <ul style="list-style-type: none"> <li>• Salary costs for permanent staff may be included in the budget with the exception of civil servants</li> <li>• Please note that salary for PhD student may only be included in the 'capacity building and training activities' component (see below).</li> </ul> </li> <li>- Travel and accommodation (only for the partner team members and for project management meetings)</li> <li>- No indirect costs/overheads</li> </ul> <p><b>For the capacity building and training activities:</b></p> <ul style="list-style-type: none"> <li>- Salary costs for support staff (technician, engineer, etc)</li> <li>- Salary for scientist, physician, veterinarian or pharmacist (short term training, PhD student, post-doctoral fellowship)</li> <li>- Travel and accommodation for exchanges programme</li> </ul> <p>Costs for project management workshops and dissemination events such as symposium are excluded</p> <p>Please note that the total amount of the "Travel and accommodation" expenses could not exceed a maximum of 8% of the total grant awarded</p>
<p><b>National phase</b></p>	<p>Not required. Only the submission of the joint proposal is required.</p>
<p><b>Further guidance</b></p>	<p>Not applicable</p>

<b>Country</b>	<b>GERMANY</b>
<b>Funding organisation</b>	<a href="#">German Federal Ministry for Education and Research (BMBF)</a>
<b>National contact persons</b>	Project Management Agency of the German Aerospace Centre (PT-DLR) - Health Research - Heinrich-Konen-Str. 1 53227 Bonn Phone: 0049 (0)228/3821-1210 Telefax: 0049 (0)228/3821-1257 E-Mail: <a href="mailto:gesundheitsforschung@dlr.de">gesundheitsforschung@dlr.de</a>
<b>National programme</b>	Framework Programme "Health Research" of the Federal Government
<b>Funding commitment</b>	About 3 Mio. €
<b>Anticipated number of fundable project partners</b>	10 – 12 research groups
<b>Maximum funding per grant awarded to a project partner</b>	-
<b>Eligibility of projects</b>	-
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, non-university public research institute, industry (note: industry is funded with a maximum of 50%-60% of the total project cost).
<b>Eligibility of principal investigator or other research team member</b>	-
<b>Eligibility of costs, types and their caps</b>	<b>For the research project as well as capacity building and training activities:</b> Personnel, consumables, animals, subcontracts, equipment, travels, documentation (all according to national regulations).
<b>National phase</b>	After the joint TRANSCAN JTC 2012 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, PT-DLR will invite those principal investigators to be funded to enter the formal national negotiations. That is, a formal proposal (written in German) must be submitted, which will formally be granted after an administrative and scientific processing (according to national regulations).
<b>Further guidance</b>	<a href="http://www.gesundheitsforschung-bmbf.de/de/4639.php">http://www.gesundheitsforschung-bmbf.de/de/4639.php</a>

<b>Country</b>	<b>ISRAEL</b>
<b>Funding organisation</b>	The Chief Scientist Office, Ministry of Health (CSO-MOH)
<b>National contact persons</b>	<b>Dr. Benny Leshem</b>
<b>National programme</b>	Medical Research Administration
<b>Funding commitment</b>	Up to 240,000 €
<b>Anticipated number of fundable project partners</b>	Up to 4
<b>Maximum funding per grant awarded to a project partner</b>	Up to 60,000 €
<b>Eligibility of projects</b>	Medical research at large
<b>Eligibility of a partner as a beneficiary institution</b>	Research institutes, hospitals in Israel
<b>Eligibility of principal investigator or other research team member</b>	PhD, MD or equivalent
<b>Eligibility of costs, types and their caps</b>	Consumables, personnel (excluding PI and Co-PI), animals, travel (ERA-Net related only), overhead. No training costs.
<b>National phase</b>	-Bio-ethics approvals, National forms. -Israeli applicants should send a copy of the project proposals to The Chief Scientist Office, Ministry of Health (CSO-MOH) in addition to the formal electronic submission to the Joint Call Secretariat (JCS).
<b>Further guidance</b>	Contact +972-2-568-1208

<b>Country</b>	<b>ITALY</b>
<b>Funding organisation</b>	<a href="#">Ministry of Health</a>
<b>National contact persons</b>	<p><b>Dr. Maria Ferrantini</b>, Ministry of Health (Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions), phone: +39 065994.2684.</p> <p><b>Dr. Tiziana Catena</b>, Ministry of Health (Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions), phone: +39 065994.3528.</p> <p><b>Dr. Silvia Paradisi</b>, Ministry of Health (Directorate General for Health and Biomedical Research and Supervision of National Health Bodies and Institutions), phone: +39 065994.2684.</p> <p>Address: Viale Giorgio Ribotta, 5 - 00144 Rome - ITALY</p> <p><b>E-mail:</b> <a href="mailto:transcan@sanita.it">transcan@sanita.it</a></p>
<b>National programme</b>	Framework National Programme "Health Research" of the Ministry of Health.
<b>Funding commitment</b>	~ 2 M€
<b>Anticipated number of fundable project partners</b>	6-7
<b>Maximum funding per grant awarded to a project partner</b>	~ 0.3 M€ per project. If a project comprises 2 Italian research groups the maximum combined amount remains the same (i.e. ~ 0.3 M€).
<b>Eligibility of projects duration</b>	Max 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	<p><b>On the basis of the D.Lgs 229/99:</b></p> <ol style="list-style-type: none"> <li>1. Regions (Regioni e Province Autonome) – Hospitals and Institutions of the National Health System.</li> <li>2. Scientific Institute for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS).</li> <li>3. National Institute of Health (Istituto Superiore di Sanità, ISS).</li> <li>4. National Institute for Occupational Safety and Prevention (Istituto Superiore per la Prevenzione e la Sicurezza sul Lavoro, INAIL ex ISPESL).</li> <li>5. National Agency for Regional Health Care Services (Agenzia Nazionale per i Servizi Sanitari Regionali, AGENAS).</li> <li>6. Universities and Research Institutions are not eligible.</li> </ol>
<b>Eligibility of principal investigator or other research team member</b>	In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants PRIOR to the <b>submission of the pre-proposals</b> . To this end, it is mandatory that the applicants return a <b>pre-eligibility check form</b> , duly completed and signed, to the e-mail address <a href="mailto:transcan@sanita.it">transcan@sanita.it</a> before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the completed and signed form is returned at least 10 working days before the pre-proposal submission deadline (15 February 2013). Applicants will be sent subsequently a written notification only in case of their ineligibility.
<b>Eligibility of costs, types and their caps</b>	Only costs generated during the lifetime of the project can be eligible. <b>For the research project:</b>

	<p>Personnel (ad hoc contracts/consultants/fellowship, no salary), travel costs and subsistence allowances, equipment (rent/leasing only), consumables, dissemination of results (publications, meetings/workshops etc.), data handling and analysis, overhead (maximum 10% of the budget requested to the Ministry of Health) (all according to national regulations).</p> <p><b>For the capacity building and training activities:</b> Travel expenses and subsistence allowances associated with training activities linked to the project.</p>
<b>National phase</b>	<p>After the joint TRANSCAN JTC 2011 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health.</p>
<b>Further guidance</b>	<p>Further information on the rules of the Ministry of Health can be found at <a href="http://www.salute.gov.it">www.salute.gov.it</a>, section "Ricerca Sanitaria", or requested to the national contact persons.</p>

<b>Country</b>	<b>LATVIA</b>
<b>Funding organisation</b>	<a href="#">Latvian Academy of Sciences</a>
<b>National contact persons</b>	<p><b>Dr. Maija Bundule</b>  <a href="mailto:maija.bundule@lza.lv">maija.bundule@lza.lv</a>  +371 67227790</p> <p><b>Dr. Uldis Berkis</b>  <a href="mailto:uberkis@latnet.lv">uberkis@latnet.lv</a>  +371 67409242</p> <p>Latvian Academy of Sciences  1 Akademijas laukums  Riga, LV-1050, Latvia</p>
<b>National programme</b>	Program "Provision of participation in EU research and technology development programs"
<b>Funding commitment</b>	250 000 € (under exceptional circumstances up to 300 000 €)
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	150 000 € (under exceptional circumstances and in case the total costs are substantially increased by costs of consumables up to 225 T€).
<b>Eligibility of projects</b>	The projects should correspond to the priorities of the TRANSCAN Call. Duration of the project - up to 3 years. The activities must correspond to "research" according to Latvian law.
<b>Eligibility of a partner as a beneficiary institution</b>	Legal bodies: universities, state research institutes, other research institutions, hospitals listed in the register of research institutions and industry (small and medium sized enterprises). If enterprises are involved, requirements of EU Regulation 800/2008 apply to financial reporting requirements for the whole consortia and each participant alone. None of the supported activities should be subject to state aid scrutiny.
<b>Eligibility of principal investigator or other research team member</b>	Principal investigator – researcher holding Dr. Or PhD degree and experienced in the field related to the project thematic. Other research team members - researchers, physicians, technicians, assistants and supporting staff.
<b>Eligibility of costs, types and their caps</b>	<p>Project eligible costs are as follows:</p> <p><b>For the research project:</b></p> <ol style="list-style-type: none"> <li>1. Personnel costs (researchers, technicians and other supporting staff to the extent employed on the research project) and relevant taxes,</li> <li>2. Other direct costs such as consumables, equipment (only depreciation costs), reagents, animals etc.,</li> <li>3. Subcontracting (up to 25% of total direct costs), with justification, includes also external patents and licenses,</li> <li>4. Travels and allowances,</li> <li>5. Overheads can reach a maximum of 20% of the total project costs, and must be justified if they exceed 10%.</li> </ol>

	<p><b>For the capacity building and training activities:</b></p> <ol style="list-style-type: none"> <li>1. Short term training related to the project needs – covering only direct costs.</li> </ol> <p>R&amp;D related costs should reach 75% of the total project funding. Core activities cannot be subcontracted.</p>
<p><b>National phase</b></p>	<ul style="list-style-type: none"> <li>- The grant will be awarded if:             <ul style="list-style-type: none"> <li>✓ the submitted project proposal of the partner of Latvia is in accordance with the criteria at the present document;</li> <li>✓ the submitted project proposal is selected for the award by the TRANSCAN Call Steering Committee;</li> <li>✓ the project Consortium Agreement is signed.</li> </ul> </li> <li>• The decision will be made by the Latvian Academy of Sciences on the base of the project ranking list by the TRANSCAN Call Steering Committee. The available budget will be taken into account.</li> </ul>
<p><b>Further guidance</b></p>	<p>The funding of RTD activities is provided pursuant in accordance with the Commissions Regulation (EC) No 800/2008 of 6 August 2008 declaring certain categories of aid compatible with the common market in application of Articles 87 and 88 of the Treaty (General block exemption Regulation), the Law on Research Activity (adopted on 14 April 2005 and as amended on 21 June 2007) and Regulations of the Council of Ministers of the Republic of Latvia No. 414 (former 722) on the procedure for providing support for participation in international cooperation programs for research and technology (adopted on 19 June 2012).</p>

<b>Country</b>	<b>LUXEMBOURG</b>
<b>Funding organisation</b>	Fonds National de la Recherche, Luxembourg
<b>National contact persons</b>	<b>Dr. Frank Glod</b> Programme Manager +352 26192533 <a href="mailto:frank.glod@fnr.lu">frank.glod@fnr.lu</a>
<b>National programme</b>	N.A.
<b>Funding commitment</b>	250.000 €
<b>Anticipated number of fundable project partners</b>	1-3
<b>Maximum funding per grant awarded to a project partner</b>	250.000 €
<b>Eligibility of projects</b>	The projects should correspond to the priorities of the TRANSCAN Call. Duration of the project - up to 3 years.
<b>Eligibility of a partner as a beneficiary institution</b>	The University of Luxembourg, the Public Research Centers, the CEPS/INSTEAD and public bodies, services and establishments authorised to undertake research and development. Full details of eligibility conditions can be found on the FNR website: <a href="http://www.fnr.lu">http://www.fnr.lu</a>
<b>Eligibility of principal investigator or other research team member</b>	The general FNR eligibility criteria apply
<b>Eligibility of costs, types and their caps</b>	Personnel including PhD students, Consumables, Animals, Subcontracts, Equipment, Travel and Documentation.
<b>National phase</b>	N.A.
<b>Further guidance</b>	N.A.

<b>Country</b>	<b>THE NETHERLANDS</b>
<b>Funding organisation</b>	<a href="#">Dutch Cancer Society (DCS / KWF Kankerbestrijding)</a>
<b>National contact persons</b>	<p><b>Dr. Wia Timmerman:</b> tel: +31-20-5700520; email: <a href="mailto:wimmerman@kwfkankerbestrijding.nl">wtimmerman@kwfkankerbestrijding.nl</a></p> <p><b>Dr. Merel Hoozemans:</b> tel: +31-20-5700520; email: <a href="mailto:mhoozemans@kwfkankerbestrijding.nl">mhoozemans@kwfkankerbestrijding.nl</a></p>
<b>National programme</b>	
<b>Funding commitment</b>	1 M€
<b>Anticipated number of fundable project partners</b>	~ 4
<b>Maximum funding per grant awarded to a project partner</b>	~ 0.25 M€
<b>Eligibility of projects</b>	Please refer to the call text.
<b>Eligibility of a partner as a beneficiary institution</b>	Please refer to the general research grant conditions of KWF Kankerbestrijding on our website
<b>Eligibility of principal investigator or other research team member</b>	Please refer to the general research grant conditions of KWF Kankerbestrijding on our website
<b>Eligibility of costs, types and their caps</b>	Please refer to the general research grant conditions of KWF Kankerbestrijding on our website
<b>National phase</b>	
<b>Further guidance</b>	The official call announcement will be published on the KWF Kankerbestrijding website ( <a href="http://www.kwfkankerbestrijding.nl">www.kwfkankerbestrijding.nl</a> ); applicants are strongly advised to contact the national contact persons.

<b>Country</b>	<b>NORWAY</b>
<b>Funding organisation</b>	The Research Council of Norway (RCN)
<b>National contact persons</b>	<b>Henrietta Blankson</b> , <a href="mailto:hbl@rcn.no">hbl@rcn.no</a> <b>Karianne Solaas</b> , <a href="mailto:kso@rcn.no">kso@rcn.no</a>
<b>National programme</b>	Publicly-initiated Clinical Cancer Studies (KREFT)
<b>Funding commitment</b>	500 000 €
<b>Anticipated number of fundable project partners</b>	1-4
<b>Maximum funding per grant awarded to a project partner</b>	
<b>Eligibility of projects</b>	Translational studies allowing a rapid implementation into public health-related decisions or into the clinics are encouraged
<b>Eligibility of a partner as a beneficiary institution</b>	Norwegian universities, university colleges, independent research institutes and other publicly funded research groups. Private industry is not eligible.
<b>Eligibility of principal investigator or other research team member</b>	The project manager should have completed a doctoral degree or have corresponding qualifications.
<b>Eligibility of costs, types and their caps</b>	Payroll expenses, grants/fellowships, procurement of R&D services, consumables, network measures.
<b>National phase</b>	
<b>Further guidance</b>	

<b>Country</b>	<b>NORWAY</b>
<b>Funding organisation</b>	Norwegian Cancer Society (NCS)
<b>National contact persons</b>	<b>Nina Anensen</b> , Research Section Tel: +47 93 00 74 07, E-mail: <a href="mailto:nina.anensen@kreftforeningen.no">nina.anensen@kreftforeningen.no</a>
<b>National programme</b>	-
<b>Funding commitment</b>	500.000 €
<b>Anticipated number of fundable project partners</b>	1 – 4
<b>Maximum funding per grant awarded to a project partner</b>	-
<b>Eligibility of projects</b>	Please refer to call text.
<b>Eligibility of a partner as a beneficiary institution</b>	Norwegian universities, university colleges, research institutes, hospitals and institutions with research as part of their activity. Private industry is not eligible.
<b>Eligibility of principal investigator or other research team member</b>	-
<b>Eligibility of costs, types and their caps</b>	<p><b>For the research project:</b></p> <ul style="list-style-type: none"> <li>- Consumables and subcontracting</li> <li>- Personnel costs (please refer also below)</li> </ul> <p><b>For the capacity building and training activities:</b></p> <ul style="list-style-type: none"> <li>- Salary of temporary staff with a specific expertise</li> <li>- Short term training dedicated to support staff (technician, engineer, etc)</li> <li>- Short term training dedicated to scientist, physician, veterinarian and pharmacist</li> <li>- PhD</li> <li>- Post-doctoral fellowship</li> <li>- Exchange programme</li> </ul> <p>Indirect costs/overhead will not be covered by The Norwegian Cancer Society.</p>
<b>National phase</b>	-
<b>Further guidance</b>	-

<b>Country</b>	<b>POLAND</b>
<b>Funding organisation</b>	National Centre for Research and Development <a href="http://www.ncbr.gov.pl">www.ncbr.gov.pl</a>
<b>National contact persons</b>	<ul style="list-style-type: none"> <li>- <b>Marcin Chmielewski</b>, Section for Research Projects BIOMED, Nowogrodzka Str. 47a, 00-695 Warsaw, Poland, +48 22 39 07 109, e-mail: <a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a>;</li> <li>- <b>Malgorzata Zieminska</b>, Section for Research Projects BIOMED, Nowogrodzka Str. 47a, 00-695 Warsaw, Poland, +48 22 39 07 140, e-mail: <a href="mailto:malgorzata.zieminska@ncbr.gov.pl">malgorzata.zieminska@ncbr.gov.pl</a></li> </ul>
<b>National programme</b>	National Scientific Research Programme ( <i>Krajowy Program Badań</i> )
<b>Funding commitment</b>	1,5 M€
<b>Anticipated number of fundable project partners</b>	3-6
<b>Maximum funding per grant awarded to a project partner</b>	The NCBR does not have a maximum funding per grant. The amount depends on the scientific needs and justification for the budget.
<b>Eligibility of projects</b>	<p>All proposals must be aligned with National regulations, inter alia:</p> <ul style="list-style-type: none"> <li>• The Act of 30 April 2010 on <b>the Principles of Financing Science</b>, published in Journal of Laws No. 96 item 615, 2010;</li> <li>• The Act of 30 April 2010 on <b>the National Centre for Research and Development</b>, published in Journal of Laws No. 96 item 616, 2010;</li> <li>• The Regulation of the Minister of Science and Higher Education of 28 October 2010 on criteria and rules on <b>granting state aid and “de minimis” aid</b> by the National Centre for Research and Development, published in Journal of Laws No. 215 item 1411, 2010.</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	<p>According to The Act of 30 April 2010 on <b>the National Centre for Research and Development</b> following entities are eligible to apply, i.a.:</p> <ul style="list-style-type: none"> <li>• Scientific institution;</li> <li>• Scientific consortia;</li> <li>• Scientific network;</li> <li>• Industrial Scientific Centre;</li> <li>• Scientific units of the Polish Academy of Sciences;</li> <li>• Legal entities with a registered seat in Poland;</li> <li>• Enterprises having the status of R&amp;D centre;</li> <li>• Enterprises conducting R&amp;D activity in other than aforementioned organizational form.</li> </ul>
<b>Eligibility of principal investigator or other research team member</b>	The cost of PHD fellowship is not eligible.

<p><b>Eligibility of costs, types and their caps</b></p>	<p><b>The eligible costs shall be the following:</b></p> <ol style="list-style-type: none"> <li>1. <b>personnel costs</b> (researchers, technicians and other supporting staff to the extent employed on the research project);</li> <li>2. <b>costs of instruments and equipment</b> to the extent and for the period used for the research project; if such instruments and equipment are not used for their full life for the research project, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice, shall be considered eligible;</li> <li>3. <b>costs for buildings and land</b>, to the extent and for the duration used for the research project; with regard to buildings, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice shall be considered eligible; for land, costs of commercial transfer or actually incurred capital costs shall be eligible;</li> <li>4. <b>cost of contractual research, technical knowledge and patents</b> bought or licensed from outside sources at market prices, where the transaction has been carried out at arm's length and there is no element of collusion involved, as well as costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more that <b>70%</b> of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel;</li> <li>5. <b>other operating costs</b>, including costs of materials, supplies and similar products incurred directly as a result of the research activity;</li> <li>6. <b>additional overheads</b> incurred indirectly as a result of the research project; that costs cannot account for more than <b>8%</b> for enterprises, <b>15%</b> for private universities and research institutes and <b>20%</b> for public universities and institutes of the Polish Academy of Sciences of all eligible project costs; That costs (6) are counted as a multiplication by percentage given above (called x%) and the rest of direct costs. It means <math>6=(1+2+3+4+5)*x\%</math>.</li> </ol> <p>The maximum rate of support for research organizations is 100% of total costs (for all type of R&amp;D); for SEs : 100% for fundamental research, max. 80% for Industrial research and max. 60% for Experimental Development of total costs; for Mes: 100% for fundamental research, max. 75% for Industrial research, max. 50% - for Experimental Development; for LE's: 100% for fundamental research, max. - 65% for Industrial research and max. 40% for Experimental Development.</p>
<p><b>National phase</b></p>	<p>Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list has been established.</p>
<p><b>Further guidance</b></p>	<ul style="list-style-type: none"> <li>• The Act of 30 April 2010 on <b>the Principles of Financing Science</b>, published in Journal of Laws No. 96 item 615, 2010;</li> <li>• The Act of 30 April 2010 on <b>the National Centre for Research and Development</b>, published in Journal of Laws No. 96 item 616, 2010;</li> <li>• The Regulation of the Minister of Science and Higher Education of 28 October 2010 on criteria and rules on <b>granting state aid and “de minimis” aid</b> by the National Centre for Research and Development, published in Journal of Laws No. 215 item 1411, 2010.</li> </ul> <p>All eligible entities, invited to submit Polish proposal are obliged to use the rate of exchange of The European Central Bank dated on the day of opening the call.</p>

<b>Country</b>	<b>PORTUGAL</b>
<b>Funding organisation</b>	<a href="#">Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia – FCT)</a>
<b>National contact persons</b>	<b>Cristiana Leandro</b> +351 213 924 381 <a href="mailto:cristiana.leandro@fct.pt">cristiana.leandro@fct.pt</a>
<b>National programme</b>	
<b>Funding commitment</b>	400.000 €
<b>Anticipated number of fundable project partners</b>	2
<b>Maximum funding per grant awarded to a project partner</b>	200.000 €
<b>Eligibility of projects</b>	All proposals must be aligned with National regulations.
<b>Eligibility of a partner as a beneficiary institution</b>	National regulations apply.
<b>Eligibility of principal investigator or other research team member</b>	National regulations apply.
<b>Eligibility of costs, types and their caps</b>	National regulations apply.
<b>National phase</b>	In the pre-proposal and in the full proposal phase no national application is needed, the electronic transnational application to the central TRANSCAN Joint Call Secretariat is sufficient. The national application by the Portuguese primary investigator to the Foundation of Science and Technology (FCT) will be mandatory for Portuguese participants, participating in those transnational projects that will be proposed for funding by the TRANSCAN Call Steering Committee.
<b>Further guidance</b>	<a href="http://www.fct.pt/apoios/cooptrans/eranets/transcan/index.phtml.pt">http://www.fct.pt/apoios/cooptrans/eranets/transcan/index.phtml.pt</a>

<b>Country</b>	<b>ROMANIA</b>
<b>Funding organisation</b>	<a href="#">Institute of Oncology Prof.Dr. Alexandru Trestioreanu (IOB)</a>
<b>National contact persons</b>	<p><b>Prof. Dr. Rodica ANGHEL, PhD MD</b>          Institute of Oncology “Prof Dr Al Trestioreanu” Bucharest          252 Fundeni street, Sector 2, Bucharest, Romania          Tel: +40 212271400          Email: <a href="mailto:rodicamanghel@gmail.com">rodicamanghel@gmail.com</a></p> <p><b>Ms. Adina STANCIU</b>          Ms. Laurentia GALES          Tel: +40 722651583          Email: <a href="mailto:lminea51269@yahoo.ca">lminea51269@yahoo.ca</a></p>
<b>National programme</b>	
<b>Funding commitment</b>	250.000 €
<b>Anticipated number of fundable project partners</b>	1-2
<b>Maximum funding per grant awarded to a project partner</b>	125.000 € for partner / 250.000 € for coordinator
<b>Eligibility of projects</b>	Joint projects
<b>Eligibility of a partner as a beneficiary institution</b>	Public institutions: clinical and non-clinical hospitals; universities; research institutes
<b>Eligibility of principal investigator or other research team member</b>	Public institutions: clinical and non-clinical hospitals; universities; research institutes
<b>Eligibility of costs, types and their caps</b>	Personnel cost, consumables, equipment, sub-contracting (max 5%), dissemination and exploitation of results, travelling connected to the project, additional costs (max 20% of direct costs)
<b>National phase</b>	
<b>Further guidance</b>	<a href="http://www.iob.ro">http://www.iob.ro</a>

<b>Country</b>	<b>SLOVAK REPUBLIC</b>
<b>Funding organisation</b>	<a href="#">Slovak Academy of Sciences (SAS)</a>
<b>National contact persons</b>	<p><b>1) Jan BARANCIK, PhD. (Coordinator)</b> Slovak Academy of Sciences, Štefánikova 49, 814 38 Bratislava, SK e-mail: <a href="mailto:barancik@up.upsav.sk">barancik@up.upsav.sk</a>, tel.: +421 2 5751 0137</p> <p><b>2) Anna GABELOVA, PhD. (Scientific Manager)</b> Cancer Research Institute, SAS, Vlarska 7 833 91 Bratislava, SK e-mail: <a href="mailto:exongaba@savba.sk">exongaba@savba.sk</a>, tel.: +421 2 59327-512, 202, 502, 526</p> <p><b>3) Iveta HERMANOVSKA (Project Manager)</b> Slovak Academy of Sciences, Štefánikova 49, 814 38 Bratislava, SK e-mail: <a href="mailto:hermanovska@up.upsav.sk">hermanovska@up.upsav.sk</a>, tel.: +421 2 5751 0136</p>
<b>National programme</b>	Research in the field of biological, medical and pharmaceutical sciences
<b>Funding commitment</b>	0,21 M €
<b>Anticipated number of fundable project partners</b>	3-5
<b>Maximum funding per grant awarded to a project partner</b>	up to 105 000 € for 3 year project period applicants from other Slovak R & D centres should cover the project costs from their own sources
<b>Eligibility of projects</b>	<p>Joint Research Projects</p> <ul style="list-style-type: none"> <li>■ 3 year transnational projects with 3 or more eligible project consortium partners and from at least 3 different TRANSCAN joint transnational call 2012 (JTC-2) funding countries</li> <li>■ Translational projects are strongly encouraged</li> </ul>
<b>Eligibility of a partner as a beneficiary institution</b>	<p>Research institutes of SAS (up to 100%)</p> <p>Applicants from other Slovak R &amp; D centers have to cover the project costs from their own sources (Letter of Commitment)</p>
<b>Eligibility of principal investigator or other research team member</b>	<ul style="list-style-type: none"> <li>■ Each researcher of the core research team of a project consortium Slovak partner (other than the Principal Investigator) must have a job contract with or a fellowship with such a Slovak project partner, lasting until the end of the project or beyond</li> <li>■ The principal Investigator of the research team of a project consortium Slovak partner must be a senior researcher having a job contract with such a project partner, lasting until the end of the granted project or beyond.</li> </ul>
<b>Eligibility of costs, types and their caps</b>	<p>Direct costs (DC) : Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs.</p> <p>Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC.</p> <p>Training costs shall not be defined as a separate category, but included in other costs items.</p>
<b>National phase</b>	Submission of the proposal at the national level will be required in parallel to the international evaluation. The submission will be carried out once the international evaluation and the ranking list have been performed and endorsed by the TRANSCAN Call Steering Committee (CSC) and the Slovak project partner has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it (Formular MVTs). The Presidium of SAS makes the final decision for funding of selected projects.
<b>Further guidance</b>	<ul style="list-style-type: none"> <li>■ Website: <a href="http://www.sav.sk/">http://www.sav.sk/</a>;</li> <li>■ 133 Act of February 19, 2002 on the Slovak Academy of Sciences.</li> <li>■ Financial rules for awarding SAS grants for research projects in frame of ERA.Net Programme for research institutes of SAS.</li> <li>■ Principles of allocation of funds for the institutes of SAS to support projects in the field of international scientific cooperation.</li> </ul>

**For more information also the NCP can be contacted.**

<b>Country</b>	<b>TURKEY</b>
<b>Funding organisation</b>	The Scientific and Technological Research Council of Turkey (TÜBİTAK) <a href="http://www.tubitak.gov.tr">http://www.tubitak.gov.tr</a> and <a href="http://www.fp7.org.tr">http://www.fp7.org.tr</a>
<b>National contact persons</b>	<b>Nihan ERYILMAZ</b> The Scientific and Technological Research Council of Turkey (TUBITAK) EU Framework Programmes National Coordination Office Tel (country code): +90- (0)312- 468 53 00 (1007) E-mail: <a href="mailto:nihan.eryilmaz@tubitak.gov.tr">nihan.eryilmaz@tubitak.gov.tr</a>
<b>National programme</b>	The Support Programme for Scientific and Technological Research Projects (1001)
<b>Funding commitment</b>	0,6 M €
<b>Anticipated number of fundable project partners</b>	3 to 4 research groups
<b>Maximum funding per grant awarded to a project partner</b>	Maximum funding per grant is 120.000 TL / year which is approximately 50.000 EUR / year (for 3 years maximum funding per grant is 360.000 TL which is approximately 150.000 EUR)
<b>Eligibility of projects</b>	3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, public research institutes, industry
<b>Eligibility of principal investigator or other research team member</b>	Principal investigators from universities and university hospitals should at least have a PhD degree. Principal investigators from public research institutes and industry should at least have a university degree.  There are other requirements related to principal investigator and other research team members. This information should be checked <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">thoroughly</a> by the Turkish partner from the web site <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm</a> before organising the research team.
<b>Eligibility of costs, types and their caps</b>	<b>For the research project:</b> Personnel, consumables, animals, subcontracts, equipment, travel, documentation. <b>For the capacity building and training activities:</b> The capacity building and training activities costs cannot be included as eligible cost.
<b>National phase</b>	1. If the project requires ethical review; After the results of the international evaluations announced (after the e-mail sent by Call Secretariat), the applicants who are awarded to be fund have to submit necessary documents stated in the rules of “The Support Programme for Scientific and Technological Research Projects – 1001” in 120 days at the latest. Original version of the “Ethics Committee Approvals - ECA” should be submitted for the projects in which ECA is needed (Letter of Applications for ECA will not be accepted for the submission).

	<p>2. If the project does not require ethical review; After the results of the international evaluations announced (after the e-mail sent by Call Secretariat), the applicants who are awarded to be fund have to submit necessary documents stated in the rules of “The Support Programme for Scientific and Technological Research Projects – 1001” in 45 days at the latest.</p>
<b>Further guidance</b>	Further information should be checked via TUBITAK’s web page on the national programme: <a href="http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm">http://www.tubitak.gov.tr/sid/367/pid/364/cid/9907/index.htm</a>